There has been much buzz lately about the side effects of Apricus Bio’s (APRI) topically applied erectile dysfunction treatment, Vitaros. Vitaros is an alprostadil-based cream and stands as a ...

Vitaros Approval in Europe On June 28, 2011 Apricus announced that its marketing application for Vitaros had been accepted for review through the European Decentralized Procedure (EDP).

The Vitaros ® product for ED incorporates Apricus Bio's proprietary postdermal and permeation enhancer using its NexACT ® technology.

The FDA has issued a complete response letter for Apricus’ topical erectile dysfunction (ED) drug Vitaros for the second time, sparking a massive after-hours slump in its share price.

SAN DIEGO, Feb. 16, 2018 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ( APRI ), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that the U.S.

Vitaros® is a topically-applied cream formulation of alprostadil, a vasodilator, combined with our proprietary permeation enhancer DDAIP.HCl, which directly increases blood flow to the penis ...

Swiss authorities have thrown cold water on Apricus Biosciences' Vitaros, a topically-applied cream for erectile dysfunction. The product has been approved in Ireland, the Netherlands, Sweden and ...

Apricus Biosciences, Inc. ( APRI ) announced the launch of its sole approved product, Vitaros in Germany. Vitaros is an on-demand topical cream.

The Company received marketing approval for Vitaros® as a first-line treatment for ED from Health Canada in November 2010, for sales of the product in that country.

The mix-up happened between her GP and pharmacist, where she was issued with Vitaros, an erectile dysfunction cream. After using it she suffered eye pain, blurred vision, redness and swollen eyelid.